TScan Therapeutics (TCRX)
NASDAQ:TCRX
Top Page
TScan Therapeutics
(NASDAQ:TCRX)
Select Model
Select Model
Rating:49Neutral
Price Target:
$0.98
▼(-0.71% Downside)
Action:ReiteratedDate:03/10/26
The score is held down primarily by weak financial performance: large ongoing losses and substantial cash burn create meaningful financing risk despite strong gross margins and a reasonable equity base. Technicals are supportive with improving momentum above key moving averages, while corporate updates add modest upside via upcoming catalysts and stated runway. Valuation remains constrained by negative earnings and no indicated dividend support.
Positive Factors
High gross margins (~91% TTM)
A ~91% gross margin is a durable structural advantage for a therapy developer: when clinical programs advance to commercial scale, low incremental cost of goods supports attractive unit economics, helps convert revenue to profit as sales scale, and gives management flexibility on pricing and partnerships.
Negative Factors
Heavy operating cash burn
Sustained, large negative operating and free cash flow implies ongoing reliance on external funding. Over time this raises dilution and refinancing risk, can constrain the pace or scope of trials, and makes long-term planning dependent on successful capital raises or partner financings.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins (~91% TTM)
A ~91% gross margin is a durable structural advantage for a therapy developer: when clinical programs advance to commercial scale, low incremental cost of goods supports attractive unit economics, helps convert revenue to profit as sales scale, and gives management flexibility on pricing and partnerships.
Read all positive factors
TScan Therapeutics (TCRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$56.25M
Dividend YieldN/A
Average Volume (3M)476.93K
Price to Earnings (P/E)―
Beta (1Y)1.92
Revenue Growth-10.03%
EPS Growth11.06%
CountryUS
Employees200
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.18
Shares Outstanding52,625,034
10 Day Avg. Volume455,904
30 Day Avg. Volume476,927
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.05
Price to Sales (P/S)12.58
P/FCF Ratio-0.93
Enterprise Value/Market Cap-0.04
Enterprise Value/Revenue-0.20
Enterprise Value/Gross Profit-0.23
Enterprise Value/Ebitda0.02
Forecast
1Y Price Target
$6.00Price Target Upside506.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.76
Revenue Forecast (FY)$7.88M
TScan Therapeutics Business Overview & Revenue Model
Company Description
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hemato...
How the Company Makes Money
TScan Therapeutics generates revenue primarily through collaboration and licensing arrangements with other biopharmaceutical companies, which may include upfront payments, research and development reimbursements, and potential milestone payments a...
TScan Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
50
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 10.32M | 2.82M | 21.05M | 13.54M | 10.14M |
| Gross Profit | 7.46M | 2.82M | 21.05M | 13.54M | 10.14M |
| EBITDA | -132.95M | -119.74M | -80.10M | -59.91M | -45.30M |
| Net Income | -129.77M | -127.50M | -89.22M | -66.22M | -48.63M |
Balance Sheet | |||||
| Total Assets | 228.79M | 371.12M | 272.15M | 199.09M | 188.11M |
| Cash, Cash Equivalents and Short-Term Investments | 152.41M | 290.11M | 192.04M | 120.03M | 161.41M |
| Total Debt | 94.14M | 97.38M | 92.43M | 85.98M | 6.04M |
| Total Liabilities | 105.67M | 130.15M | 121.28M | 99.66M | 27.33M |
| Stockholders Equity | 123.12M | 240.97M | 150.87M | 99.43M | 160.78M |
Cash Flow | |||||
| Free Cash Flow | -139.73M | -114.65M | -64.50M | -70.73M | -58.62M |
| Operating Cash Flow | -135.32M | -110.82M | -61.36M | -66.50M | -48.68M |
| Investing Cash Flow | 109.37M | -52.61M | -60.76M | -4.22M | -9.94M |
| Financing Cash Flow | -336.00K | 208.76M | 135.44M | 29.36M | 189.67M |
TScan Therapeutics Technical Analysis
Negative
0.99
Price Trends
1.06
Negative
1.06
Negative
1.44
Negative
Market Momentum
-0.01
Positive
40.10
Neutral
19.91
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCRX, the sentiment is Negative. The current price of 0.99 is below the 20-day moving average (MA) of 1.08, below the 50-day MA of 1.06, and below the 200-day MA of 1.44, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 40.10 is Neutral, neither overbought nor oversold. The STOCH value of 19.91 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TCRX.
TScan Therapeutics Risk Analysis
TScan Therapeutics disclosed 106 risk factors in its most recent earnings report. TScan Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
TScan Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $268.48M | -0.60 | -118.95% | ― | ― | 31.98% | |
53 Neutral | $148.96M | -0.71 | -57.49% | ― | -33.76% | 17.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $56.25M | -1.00 | -71.28% | ― | -10.03% | 11.06% | |
47 Neutral | $331.97M | -0.70 | ― | ― | -63.96% | -28.50% | |
44 Neutral | $221.81M | -4.18 | -46.90% | ― | -100.00% | 79.01% | |
43 Neutral | $52.83M | -1.03 | -58.78% | ― | ― | 1.40% |
* Healthcare Sector Average
TCRX
TScan Therapeutics
0.99
-0.39
-28.41%
ZNTL
Zentalis Pharmaceuticals
2.10
0.51
32.08%
ALXO
ALX Oncology Holdings
2.04
1.42
229.03%
IKT
Inhibikase Therapeutics
1.68
-0.51
-23.29%
SRZN
Surrozen
28.90
17.24
147.86%
TIL
Instil Bio
7.79
-9.57
-55.13%
TScan Therapeutics Corporate Events
Business Operations and StrategyFinancial Disclosures
TScan Therapeutics Outlines Pivotal 2026 Outlook in Presentation
Positive
Jan 12, 2026
On January 12, 2026, TScan Therapeutics made public a new corporate presentation timed with the 44th Annual J.P. Morgan Healthcare Conference, detailing what it characterizes as a highly active 2026 outlook built around a pivotal trial launch for ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.